Sign In
Buy CPRX
$31.28
+0.0100 (+0.0320%)
At Close: Jun 03, 2026
Contrasting Organogenesis (NASDAQ:ORGO) & Catalyst Pharmaceuticals (NASDAQ:CPRX)
01:14am, Sunday, 28'th Dec 2025
Catalyst Pharmaceuticals (NASDAQ: CPRX - Get Free Report) and Organogenesis (NASDAQ: ORGO - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two co
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock
10:51am, Tuesday, 23'rd Dec 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Toth Financial Advisory Corp Has $42,000 Stake in Catalyst Pharmaceuticals, Inc. $CPRX
05:32am, Monday, 22'nd Dec 2025
Toth Financial Advisory Corp trimmed its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) by 96.5% in the third quarter, according to its most recent Form 13F filing with the Securi
Insider Selling: Catalyst Pharmaceuticals (NASDAQ:CPRX) Director Sells $621,844.50 in Stock
04:44am, Friday, 19'th Dec 2025
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX - Get Free Report) Director Molly Harper sold 26,746 shares of the firm's stock in a transaction dated Friday, December 12th. The shares were sold at an av
CPRX vs. DSNKY: Which Stock Is the Better Value Option?
12:41pm, Wednesday, 17'th Dec 2025
Investors interested in Medical - Drugs stocks are likely familiar with Catalyst Pharmaceutical (CPRX) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).
Wall Street Analysts See a 42.62% Upside in Catalyst (CPRX): Can the Stock Really Move This High?
10:56am, Wednesday, 17'th Dec 2025
The mean of analysts' price targets for Catalyst (CPRX) points to a 42.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst
Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock?
10:40am, Wednesday, 17'th Dec 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference
08:03am, Monday, 15'th Dec 2025
CORAL GABLES, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, de
Catalyst Pharmaceuticals, Inc. (CPRX) Presents at BofA Securities CNS Therapeutics Virtual Conference 2025 Transcript
04:07pm, Monday, 08'th Dec 2025
Catalyst Pharmaceuticals, Inc. (CPRX) Presents at BofA Securities CNS Therapeutics Virtual Conference 2025 Transcript
Catalyst (CPRX) Up 10% Since Last Earnings Report: Can It Continue?
12:36pm, Friday, 05'th Dec 2025
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
Catalyst Pharmaceutical (CPRX) Recently Broke Out Above the 20-Day Moving Average
10:35am, Thursday, 04'th Dec 2025
From a technical perspective, Catalyst Pharmaceutical (CPRX) is looking like an interesting pick, as it just reached a key level of support. CPRX recently overtook the 20-day moving average, and this
Catalyst Pharmaceuticals, Inc. (CPRX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
04:43pm, Tuesday, 02'nd Dec 2025
Catalyst Pharmaceuticals, Inc. (CPRX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term
10:52am, Tuesday, 02'nd Dec 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
CPRX or DSNKY: Which Is the Better Value Stock Right Now?
12:48pm, Monday, 01'st Dec 2025
Investors looking for stocks in the Medical - Drugs sector might want to consider either Catalyst Pharmaceutical (CPRX) or Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).
Wall Street Analysts Think Catalyst (CPRX) Could Surge 47.37%: Read This Before Placing a Bet
10:56am, Monday, 01'st Dec 2025
The mean of analysts' price targets for Catalyst (CPRX) points to a 47.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst
